BMO Capital Markets gave Halozyme (NASDAQ: HALO ) an upgrade today, pushing the company's price target up from $4 to an incredible $12, which has shares up 15%. In the following video, Motley Fool health care analyst David Williamson takes us through BMO's thought process for an upgrade and Halozyme's upcoming catalysts.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. Make sure you start 2013 with a bang and get the inside scoop on what Motley Fool Superinvestor David Gardner will be buying this year. He's crushed the market in his Stock Advisor and Rule Breakers portfolios for years, and now I invite you to a personal tour of his flagship stock-picking service: Supernova. Just click here now for instant access.